We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal
Read MoreHide Full Article
Shares of Aptinyx were down 36.67% pre-market on Jul 12, after the company announced disappointing results from the phase IIb study of NYX-2925 in patients with fibromyalgia.
The phase IIb study is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of NYX-295 as a treatment for patients with fibromyalgia. The clinical study enrolled approximately 300 patients.
Aptinyx tested two doses (50 mg and 100 mg) of the treatment in patients with fibromyalgia, against a dose of placebo, once daily, over the treatment period.
The study’s primary endpoint was the change from baseline in average daily pain as reported on the zero-to-ten numeric rating scale during week 12 of the study.
However, the study did not meet its primary endpoint.
By week four of the study, patients treated with both doses of NYX-2925 did show a clinically meaningful improvement in pain compared with placebo, which by week 12, although numerically better, was not clinically significant.
Both treatment doses were well-tolerated in patients and had no safety concerns. The detailed data from the study will continue to be evaluated.
Shares of Aptinyx have fallen 85.4% year-to-date, compared to the industry’s decline of 17.8%
Image Source: Zacks Investment Research
Earlier this year, the company suffered another setback as NYX-2925, being evaluated for treating patients with painful diabetic peripheral neuropathy (“DPN”) had failed to achieve its primary endpoint in a phase IIb study.
Aptinyx is a clinical-stage biopharma company focused on the development of proprietary synthetic small molecules for treating brain and nervous system disorders.
BioMarin’s earnings estimates for 2022 have improved from $1.95 per share to $2.01 over the past 30 days. Shares of BMRN have returned 7.7% year to date. Earnings of BioMarin beat estimates in all of the last four quarters. BMRN delivered an earnings surprise of 98.90%, on average.
Epizyme’s loss estimates for 2022 have narrowed down from $1.38 per share to $1.36 over the past 30 days. Shares of EPZM have fallen 41.2% year to date. Earnings of Epizyme missed estimates in three of the last four quarters, while beating the same in one occasion. EPZM delivered a negative earnings surprise of 7.87%, on average.
Inozyme’s loss estimates for 2022 have narrowed from $2.10 per share to $2.08 per share over the past 30 days. Shares of INZY have declined 49.1% year to date. Earnings of Inozyme beat estimates in three of the last four quarters and missed the mark on one occasion. INZY delivered an earnings surprise of 3.20%, on average.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal
Shares of Aptinyx were down 36.67% pre-market on Jul 12, after the company announced disappointing results from the phase IIb study of NYX-2925 in patients with fibromyalgia.
The phase IIb study is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of NYX-295 as a treatment for patients with fibromyalgia. The clinical study enrolled approximately 300 patients.
Aptinyx tested two doses (50 mg and 100 mg) of the treatment in patients with fibromyalgia, against a dose of placebo, once daily, over the treatment period.
The study’s primary endpoint was the change from baseline in average daily pain as reported on the zero-to-ten numeric rating scale during week 12 of the study.
However, the study did not meet its primary endpoint.
By week four of the study, patients treated with both doses of NYX-2925 did show a clinically meaningful improvement in pain compared with placebo, which by week 12, although numerically better, was not clinically significant.
Both treatment doses were well-tolerated in patients and had no safety concerns. The detailed data from the study will continue to be evaluated.
Shares of Aptinyx have fallen 85.4% year-to-date, compared to the industry’s decline of 17.8%
Image Source: Zacks Investment Research
Earlier this year, the company suffered another setback as NYX-2925, being evaluated for treating patients with painful diabetic peripheral neuropathy (“DPN”) had failed to achieve its primary endpoint in a phase IIb study.
Aptinyx is a clinical-stage biopharma company focused on the development of proprietary synthetic small molecules for treating brain and nervous system disorders.
Aptinyx Inc. Price
Aptinyx Inc. price | Aptinyx Inc. Quote
Zacks Rank and Stocks to Consider
Aptinyx currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the same sector are BioMarin Pharmaceutical (BMRN - Free Report) , Epizyme and Inozyme Pharma (INZY - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
BioMarin’s earnings estimates for 2022 have improved from $1.95 per share to $2.01 over the past 30 days. Shares of BMRN have returned 7.7% year to date. Earnings of BioMarin beat estimates in all of the last four quarters. BMRN delivered an earnings surprise of 98.90%, on average.
Epizyme’s loss estimates for 2022 have narrowed down from $1.38 per share to $1.36 over the past 30 days. Shares of EPZM have fallen 41.2% year to date. Earnings of Epizyme missed estimates in three of the last four quarters, while beating the same in one occasion. EPZM delivered a negative earnings surprise of 7.87%, on average.
Inozyme’s loss estimates for 2022 have narrowed from $2.10 per share to $2.08 per share over the past 30 days. Shares of INZY have declined 49.1% year to date. Earnings of Inozyme beat estimates in three of the last four quarters and missed the mark on one occasion. INZY delivered an earnings surprise of 3.20%, on average.